Open-label phase II study of everolimus plus endocrine therapy in post-menopausal women with ER+, HER2-metastatic breast cancer (Chloe trial)

被引：0
|
作者：
Shien, T. [1 ]
Shimomura, A. [2 ]
Uemura, Y. [3 ]
Kato, H. [4 ]
Kitada, M. [5 ]
Kikawa, Y. [6 ]
Shiba, E. [7 ]
Yoshida, T. [8 ]
Morimoto, T. [9 ]
Toyama, T. [10 ]
Aihara, T. [11 ]
Mukai, H. [12 ]
机构：
[1] Okayama Univ Hosp, Breast & Endocrine Surg, Okayama, Japan
[2] Natl Canc Ctr, Breast & Med Oncol, Tokyo, Japan
[3] Tokyo Univ Hosp, Biostat, Clin Res Support Ctr, Tokyo, Japan
[4] Teine Keijinkai Hosp, Thorac Surg, Sapporo, Hokkaido, Japan
[5] Asahikawa Med Univ, Surg, Asahikawa, Hokkaido, Japan
[6] Gen Hosp, Kobe City Med Ctr, Breast Surg, Kobe, Hyogo, Japan
[7] Osaka Breast Clin, Surg, Osaka, Japan
[8] Kanagawa Canc Ctr, Breast & Endocrine Surg, Yokohama, Kanagawa, Japan
[9] Yao Municipal Hosp, Breast Surg, Osaka, Japan
[10] Nagoya City Univ, Grad Sch Med Sci, Breast Surg, Nagoya, Aichi, Japan
[11] Keimeikai Aihara Hosp, Surg, Osaka, Japan
[12] Natl Canc Ctr Hosp East, Breast & Med Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
313TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Open-label phase II study of everolimus plus endocrine therapy in postmenopausal women with ER+, HER2-metastatic breast cancer (Chloe trial)
    Shien, Tadahiko
    Kitada, Masahiro
    Uemura, Yukari
    Kato, Hiroaki
    Kikawa, Yuichiro
    Shimomura, Akihiko
    Watanabe, Kenichi
    Kojima, Yasuyuki
    Yokota, Toru
    Kamei, Yoshiaki
    Nishimura, Reiki
    Nagashima, Takeshi
    Hashimoto, Naoki
    Sakaguchi, Koichi
    Yamashita, Toshinari
    Harano, Kenichi
    Yonemori, Kan
    Horimoto, Yoshiya
    Mukai, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)
    Shimoi, Tatsunori
    Shimomura, Akihiko
    Shien, Tadahiko
    Uemura, Yukari
    Kato, Hiroaki
    Kitada, Masahiro
    Toyama, Tatsuya
    Aihara, Tomohiko
    Mukai, Hirofumi
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2018, 10 : 13 - 18
  • [3] BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+, HER2- metastatic breast cancer.
    Gradishar, William John
    Bachelot, Thomas Denis
    Saletan, Stephen
    Graham, Anne Marie
    Rubini Liedke, Pedro Emanuel
    Azevedo, Sergio Jobim
    Sriuranpong, Virote
    Cardoso, Fatima
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] BOLERO-5: A phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER+/HER2-advanced breast cancer
    Shao, Z.
    Cai, L.
    Wang, S.
    Hu, X.
    Shen, K.
    Wang, H.
    Li, H.
    Feng, J.
    Liu, Q.
    Cheng, J.
    Wu, X.
    Wang, X.
    Li, H.
    Luo, T.
    Liu, J.
    Amin, K.
    Slimane, K.
    Qiao, Y.
    Liu, Y.
    Tong, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S463 - S463
  • [5] Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.
    Bardia, Aditya
    Modi, Shanu
    Gregor, Mariana Chavez-Mac
    Kittaneh, Muaiad
    Marino, Alyssa J.
    Matano, Alessandro
    Bhansali, Suraj
    Hewes, Becker
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] PYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2-metastatic breast cancer
    Zardavas, D.
    Regan, M.
    Maibach, R.
    Ruepp, B.
    Hiltbrunner, A.
    Blacher, L.
    Gelber, R.
    Gebhart, G.
    Di Leo, A.
    Hilbers, F.
    Colleoni, M.
    Zoppoli, G.
    Bertelli, G.
    Bliss, J.
    Duhoux, F.
    Piccart, M.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Treatment patterns and characteristics of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus.
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] SOCIETAL COSTS OF ER+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN POST-MENOPAUSAL WOMEN IN THE UNITED KINGDOM
    Bermingham, S.
    Schmid, P.
    Forster, F.
    Comic, L.
    Theti, D.
    Smith, A.
    VALUE IN HEALTH, 2017, 20 (09) : A427 - A427
  • [9] Everolimus Plus Letrozole for Treatment of Patients With HR+, HER2- Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial
    Safra, Tamar
    Kaufman, Bella
    Kadouri, Luna
    Efrat , Noa
    Ryvo, Larisa
    Nisenbaum, Bella
    Evron, Ella
    Yerushalmi, Rinat
    CLINICAL BREAST CANCER, 2018, 18 (02) : E197 - E203
  • [10] TREATMENT PATTERNS OF ENDOCRINE THERAPY AND CHEMOTHERAPY AMONG POST-MENOPAUSAL WO MEN WITH HR+/HER2-METASTATIC BREAST CANCER
    Lin, P. L.
    Hao, Y.
    Signorovitch, J. E.
    Kelley, C.
    Macalalad, A. R.
    Ohashi, E.
    Zhou, Z.
    Wu, E. Q.
    VALUE IN HEALTH, 2015, 18 (03) : A1221 - A1221
12345